Literature DB >> 11325528

Regulation of the ErbB3 binding protein Ebp1 by protein kinase C.

T J Lessor1, A W Hamburger.   

Abstract

Ebp1, a 47 kDa ubiquituously expressed protein, binds the ErbB3 receptor in human serum starved breast cancer cell lines and dissociates from ErbB3 on treatment with the ErbB3 ligand, Heregulin (HRG). However, the mechanism of Ebp1-ErbB3 association/dissociation is not understood. Since Ebp1 contains six putative Protein Kinase C serine/threonine phosphorylation sites, we examined the ability of PKC to phosphorylate Ebp1 and to regulate Ebp1-ErbB3 binding. We found that Ebp1 was basally phosphorylated in AU565 breast cancer cells on serine/threonine residues and that this phosphorylation was enhanced by heregulin treatment. Both serine and threonine residues of a GST-Ebp1 fusion protein were phosphorylated by PKC in vitro. In vivo, we demonstrated that basal Ebp1 phosphorylation was dependent upon PKC. However, HRG-induced phosphorylation of Ebp1 occurred predominantly in a PKC-independent manner. The ability of Ebp1 to associate with ErbB3 in serum-starved NIH3T3 cells overexpresssing ErbB3 was abrogated by treating cells with a PKC inhibitor. These findings suggest that PKC plays a role in regulating phosphorylation and function of Ebp1 in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325528     DOI: 10.1016/s0303-7207(01)00387-2

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase.

Authors:  Jee-Yin Ahn; Xia Liu; Zhixue Liu; Lorena Pereira; Dongmei Cheng; Junmin Peng; Paul A Wade; Anne W Hamburger; Keqiang Ye
Journal:  EMBO J       Date:  2006-04-27       Impact factor: 11.598

2.  Ebp1 isoforms distinctively regulate cell survival and differentiation.

Authors:  Zhixue Liu; Jee-Yin Ahn; Xia Liu; Keqiang Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-10       Impact factor: 11.205

Review 3.  The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.

Authors:  Anne W Hamburger
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-19       Impact factor: 2.673

4.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block.

Authors:  Maitreyee K Jathal; Liqun Chen; Maria Mudryj; Paramita M Ghosh
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011-06

5.  Modulation of HCV replication and translation by ErbB3 binding protein1 isoforms.

Authors:  Priya Mishra; Updesh Dixit; Ashutosh K Pandey; Alok Upadhyay; Virendra N Pandey
Journal:  Virology       Date:  2016-10-19       Impact factor: 3.616

6.  High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC).

Authors:  Chen Gong; Yixin Zhang; Yinji Chen; Haifeng Zhang; Xiaorong Liu; Huaqing Xue; Li Ji; Liang Wang; Linlin Yang; Guoxiong Zhou; Chunhua Wan
Journal:  Tumour Biol       Date:  2015-06-19

Review 7.  A structural view of PA2G4 isoforms with opposing functions in cancer.

Authors:  Brendan W Stevenson; Michael A Gorman; Jessica Koach; Belamy B Cheung; Glenn M Marshall; Michael W Parker; Jessica K Holien
Journal:  J Biol Chem       Date:  2020-09-20       Impact factor: 5.157

Review 8.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

9.  Structural insights into the transcriptional and translational roles of Ebp1.

Authors:  Tom P Monie; Andrew J Perrin; James R Birtley; Trevor R Sweeney; Ioannis Karakasiliotis; Yasmin Chaudhry; Lisa O Roberts; Stephen Matthews; Ian G Goodfellow; Stephen Curry
Journal:  EMBO J       Date:  2007-08-09       Impact factor: 11.598

10.  Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells.

Authors:  D Akinmade; A H Talukder; Y Zhang; W-M Luo; R Kumar; A W Hamburger
Journal:  Br J Cancer       Date:  2008-02-19       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.